Jubilant Pharmova Limited

NSEI:JUBLPHARMA 주식 보고서

시가총액: ₹117.6b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Jubilant Pharmova 미래 성장

Future 기준 확인 0/6

현재 Jubilant Pharmova 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Pharmaceuticals 수익 성장17.1%
매출 성장률n/a
향후 자기자본 수익률n/a
애널리스트 커버리지

None

마지막 업데이트n/a

최근 미래 성장 업데이트

Recent updates

Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet

Mar 14
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet

Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth

Dec 23
Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth

These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively

Dec 02
These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively

These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively

Jul 26
These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively

Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)

May 11
Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?

Dec 10
Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?

Jubilant Pharmova (NSE:JUBLPHARMA) Has Announced A Dividend Of ₹5.00

Aug 01
Jubilant Pharmova (NSE:JUBLPHARMA) Has Announced A Dividend Of ₹5.00

Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?

Jun 15
Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?

Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Mar 22
Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?

Feb 15
Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?

Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Dec 20
Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Here's Why It's Unlikely That Jubilant Pharmova Limited's (NSE:JUBLPHARMA) CEO Will See A Pay Rise This Year

Sep 15
Here's Why It's Unlikely That Jubilant Pharmova Limited's (NSE:JUBLPHARMA) CEO Will See A Pay Rise This Year

Here's Why Jubilant Pharmova (NSE:JUBLPHARMA) Can Manage Its Debt Responsibly

Aug 21
Here's Why Jubilant Pharmova (NSE:JUBLPHARMA) Can Manage Its Debt Responsibly

Time To Worry? Analysts Are Downgrading Their Jubilant Pharmova Limited (NSE:JUBLPHARMA) Outlook

Jun 08
Time To Worry? Analysts Are Downgrading Their Jubilant Pharmova Limited (NSE:JUBLPHARMA) Outlook

An Intrinsic Calculation For Jubilant Pharmova Limited (NSE:JUBLPHARMA) Suggests It's 39% Undervalued

May 25
An Intrinsic Calculation For Jubilant Pharmova Limited (NSE:JUBLPHARMA) Suggests It's 39% Undervalued

Analysts Just Made A Major Revision To Their Jubilant Pharmova Limited (NSE:JUBILANT) Revenue Forecasts

Feb 10
Analysts Just Made A Major Revision To Their Jubilant Pharmova Limited (NSE:JUBILANT) Revenue Forecasts

Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBILANT)

Feb 08
Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBILANT)

Shareholders Are Thrilled That The Jubilant Life Sciences (NSE:JUBILANT) Share Price Increased 217%

Jan 11
Shareholders Are Thrilled That The Jubilant Life Sciences (NSE:JUBILANT) Share Price Increased 217%

Does Jubilant Life Sciences' (NSE:JUBILANT) CEO Salary Compare Well With Industry Peers?

Dec 31
Does Jubilant Life Sciences' (NSE:JUBILANT) CEO Salary Compare Well With Industry Peers?

Read This Before Selling Jubilant Life Sciences Limited (NSE:JUBILANT) Shares

Dec 20
Read This Before Selling Jubilant Life Sciences Limited (NSE:JUBILANT) Shares

Has Jubilant Life Sciences Limited's (NSE:JUBILANT) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Dec 08
Has Jubilant Life Sciences Limited's (NSE:JUBILANT) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

We Think Jubilant Life Sciences (NSE:JUBILANT) Can Stay On Top Of Its Debt

Nov 27
We Think Jubilant Life Sciences (NSE:JUBILANT) Can Stay On Top Of Its Debt

What Kind Of Investors Own Most Of Jubilant Life Sciences Limited (NSE:JUBILANT)?

Nov 17
What Kind Of Investors Own Most Of Jubilant Life Sciences Limited (NSE:JUBILANT)?

Jubilant Life Sciences Limited Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next

Nov 06
Jubilant Life Sciences Limited Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next

If You Like EPS Growth Then Check Out Jubilant Life Sciences (NSE:JUBILANT) Before It's Too Late

Oct 27
If You Like EPS Growth Then Check Out Jubilant Life Sciences (NSE:JUBILANT) Before It's Too Late

Estimating The Fair Value Of Jubilant Life Sciences Limited (NSE:JUBILANT)

Oct 15
Estimating The Fair Value Of Jubilant Life Sciences Limited (NSE:JUBILANT)

Does Jubilant Life Sciences' (NSE:JUBILANT) Share Price Gain of 96% Match Its Business Performance?

Oct 03
Does Jubilant Life Sciences' (NSE:JUBILANT) Share Price Gain of 96% Match Its Business Performance?

Trade Alert: The Independent Non-Executive Director Of Jubilant Life Sciences Limited (NSE:JUBILANT), Arun Seth, Has Just Spent ₹1.1m Buying 233% More Shares

Sep 21
Trade Alert: The Independent Non-Executive Director Of Jubilant Life Sciences Limited (NSE:JUBILANT), Arun Seth, Has Just Spent ₹1.1m Buying 233% More Shares

How Much is Jubilant Life Sciences' (NSE:JUBILANT) CEO Getting Paid?

Sep 20
How Much is Jubilant Life Sciences' (NSE:JUBILANT) CEO Getting Paid?

Jubilant Life Sciences Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Sep 08
Jubilant Life Sciences Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Jubilant Pharmova 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

NSEI:JUBLPHARMA - 애널리스트의 미래 추정치 및 과거 재무 데이터 (INR Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
3/31/202467,0297717369,713N/A
12/31/202366,223378N/AN/AN/A
9/30/202364,977-4461339,836N/A
6/30/202364,169-1,017N/AN/AN/A
3/31/202362,817-610-1,5386,607N/A
12/31/202261,313964N/AN/AN/A
9/30/202258,8931,631-1,5964,924N/A
6/30/202259,4723,004N/AN/AN/A
3/31/202261,3024,1392,3768,375N/A
12/31/202161,8245,273N/AN/AN/A
9/30/202166,4326,95310,17516,021N/A
6/30/202165,7716,993N/AN/AN/A
3/31/202160,9855,74112,56817,843N/A
12/31/202092,6598,339N/AN/AN/A
9/30/202089,7447,75910,03115,596N/A
6/30/202088,6558,013N/AN/AN/A
3/31/202059,7586,7789,68815,429N/A
12/31/201991,4865,385N/AN/AN/A
9/30/201992,1055,9597,35713,374N/A
6/30/201992,1405,569N/AN/AN/A
3/31/201991,1085,7454,65611,215N/A
12/31/201889,7728,286N/AN/AN/A
9/30/201886,6797,803N/AN/AN/A
6/30/201880,4026,982N/AN/AN/A
3/31/201875,1786,4288,14113,032N/A
12/31/201768,6416,381N/AN/AN/A
9/30/201762,5455,449N/AN/AN/A
6/30/201759,9825,613N/AN/AN/A
3/31/201758,6145,757N/A12,685N/A
12/31/201658,0134,763N/AN/AN/A
9/30/201657,0974,795N/AN/AN/A
6/30/201657,7624,612N/AN/AN/A
3/31/201657,4913,918N/A10,989N/A
12/31/201558,3764,035N/AN/AN/A
9/30/201559,0362,754N/AN/AN/A
6/30/201558,117655N/AN/AN/A
3/31/201558,262-578N/A7,833N/A
12/31/201458,863-17N/AN/AN/A
9/30/201458,8371,529N/AN/AN/A
6/30/201458,6411,664N/AN/AN/A
3/31/201458,0341,090N/A7,723N/A
12/31/201355,983-207N/AN/AN/A
9/30/201354,658-1,375N/AN/AN/A

애널리스트 미래 성장 예측

수입 대 저축률: JUBLPHARMA 의 예상 수익 증가율이 절약률( 6.7% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: JUBLPHARMA 의 수익이 Indian 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: JUBLPHARMA 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: JUBLPHARMA 의 수익이 Indian 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: JUBLPHARMA 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: JUBLPHARMA 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

성장 기업 발견

7D

1Y

7D

1Y

7D

1Y